Mylan NV (NASDAQ: MYL), a global pharmaceutical company, announced yesterday that it has launched its Medroxyprogesterone Acetate Injectable (MPA) Suspension USP, 150mg/mL Single-Dose Vial, a generic version of the brand drug, Pfizer's Depo-Provera, in the United States.
The company is providing the product, which is indicated in the prevention of pregnancy, to its institutional customers after an Abbreviated New Drug Application for the product was approved by the US Food and Drug Administration (FDA).
Mylan CEO, Heather Bresch, said, 'The launch of Medroxyprogesterone Acetate adds to Mylan's robust portfolio of generic birth control medicines in the US. These products are part of Mylan's growing women's healthcare offerings, which include a variety of medicines to help women manage their health across all the stages of their lives.'
US sales for MPA were approximately USD181 million for the 12 months ending 31 July 2018.
Amneal Pharmaceuticals appoints David A. Buchen as SVP, chief legal officer and corporate secretary
Ironwood Pharmaceuticals and Allergan reach agreement to resolve Mylan LINZESS patent litigation
Teva and Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalet HCl Product
Ironwood, Allergan Agree Settlement with Mylan Resolving Linzess Patent Litigation
Teva announces resolution of litigation with Amgen over Teva's generic cinacalet HCl product
Innovent's phase III clinical trial of anti-PD-1 antibody Tyvyt reports first patient dosing
Dr. Reddy's Laboratories Launches Sevelamer Carbonate for Oral Suspension in the US Market